Skip to main content

Peer Review reports

From: Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC

Original Submission
9 Sep 2021 Submitted Original manuscript
13 Oct 2021 Reviewed Reviewer Report
15 Oct 2021 Reviewed Reviewer Report - ABDELKRIM ALILECHE
1 Dec 2021 Author responded Author comments - Lisa Faoro
Resubmission - Version 2
1 Dec 2021 Submitted Manuscript version 2
28 Dec 2021 Reviewed Reviewer Report - ABDELKRIM ALILECHE
3 Feb 2022 Reviewed Reviewer Report
17 Feb 2022 Author responded Author comments - Lisa Faoro
Resubmission - Version 3
17 Feb 2022 Submitted Manuscript version 3
21 Mar 2022 Reviewed Reviewer Report
29 Jul 2022 Author responded Author comments - Lisa Faoro
Resubmission - Version 4
29 Jul 2022 Submitted Manuscript version 4
12 Oct 2022 Reviewed Reviewer Report
23 Nov 2022 Author responded Author comments - Lisa Faoro
Resubmission - Version 5
23 Nov 2022 Submitted Manuscript version 5
1 Dec 2022 Author responded Author comments - Lisa Faoro
Resubmission - Version 6
1 Dec 2022 Submitted Manuscript version 6
8 Dec 2022 Author responded Author comments - Lisa Faoro
Resubmission - Version 7
8 Dec 2022 Submitted Manuscript version 7
23 Dec 2022 Author responded Author comments - Lisa Faoro
Resubmission - Version 8
23 Dec 2022 Submitted Manuscript version 8
15 Feb 2023 Author responded Author comments - Lisa Faoro
Resubmission - Version 9
15 Feb 2023 Submitted Manuscript version 9
5 Mar 2023 Author responded Author comments - Lisa Faoro
Resubmission - Version 10
5 Mar 2023 Submitted Manuscript version 10
Publishing
14 Mar 2023 Editorially accepted
15 May 2023 Article published 10.1186/s40360-023-00663-0

You can find further information about peer review here.

Back to article page